Search Result
15 search results for Histiocytic Neoplasms
NCCN Guidelines Histiocytic Neoplasms
NCCN Guidelines Histiocytic Neoplasms, NCCN clinical practice guidelines in oncology – Histiocytic Neoplasms
https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdfErdheim-Chester Disease
NCCN clinical practice guidelines in oncology – Histiocytic Neoplasms
https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdfLangerhans Cell Histiocytosis
NCCN clinical practice guidelines in oncology – Histiocytic Neoplasms
https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdfRosai-Dorfman Disease
NCCN clinical practice guidelines in oncology – Histiocytic Neoplasms
https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdfPermission to Cite or Use NCCN Content
Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma Kidney Cancer Lung, Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma Kidney Cancer, Hematopoietic Growth Factors Hepatobiliary Cancers Hepatocellular Carcinoma Histiocytic Neoplasms, Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma Kidney Cancer Management, Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma Kidney Cancer Melanoma: Cutaneous Melanoma
https://www.nccn.org/guidelines/permission-to-cite-or-use-nccn-contentTransparency Process
Histiocytic Neoplasms Panel, Version: 1.2023 ( Histiocytic Neoplasms ) Date: 2022-12-02 Transparency Panel Disclosures/Attendance Version: 1.2022 ( Histiocytic Neoplasms ) Date: 2021-12-16, Transparency Panel Disclosures/Attendance Version: 3.2024 ( Uterine Neoplasms, Version: 2.2024 ( Uterine Neoplasms ) Date: 2024-02-29 Transparency Panel Disclosures
https://www.nccn.org/guidelines/guidelines-process/transparency-process-and-recommendationsGuidelines Panels
Cancers Panel Histiocytic Neoplasms, Myeloproliferative Neoplasms Panel
https://www.nccn.org/guidelines/guidelines-panels-and-disclosure/disclosure-panelsTreatment by Cancer Type
Version: 3.2024 Histiocytic Neoplasms, Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Version: 2.2024 Myeloproliferative Neoplasms, Neoplasms Version: 3.2024 Vaginal Cancer
https://www.nccn.org/guidelines/category_1Resume Screening
Hepatobiliary Cancers Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi, Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Myeloproliferative Neoplasms Neuroblastoma, Thymomas and Thymic Carcinomas Thyroid Carcinoma Uterine Neoplasms Vaginal Cancer Vulvar, Mesothelioma Mouth Cancer Multiple Myeloma Myelodysplastic Syndromes Myeloproliferative Neoplasms
https://www.nccn.org/covid-19/resume-screeningSubmission Request Form
- 1.2025 Hepatobiliary Cancers - 1.2023 Hepatocellular Carcinoma - 3.2024 Histiocytic Neoplasms - 2.2024, /Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions - 2.2024 Myeloproliferative Neoplasms - 2.2024 Neuroblastoma - 2.2024 Neuroendocrine and Adrenal Tumors - 2.2024 Non-Small Cell Lung, - 4.2024 Uterine Neoplasms - 3.2024 Vaginal Cancer - 2.2025 Vulvar Cancer - 4.2024 Waldenström
https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-formGuidelines With Evidence Blocks
Version 5.2024 Hepatocellular Carcinoma Version 3.2024 Histiocytic Neoplasms Version, Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Version 2.2024 Myeloproliferative Neoplasms Version 2.2024 Neuroendocrine and Adrenal Tumors, Version 1.2024 Thyroid Carcinoma Version 4.2024 Uterine Neoplasms Version 3.2024
https://www.nccn.org/guidelines/guidelines-with-evidence-blocksChemotherapy Order Templates Reviewer Acknowledgement
Roswell Park Comprehensive Cancer Center Histiocytic Neoplasms, Moffitt Cancer Center Myeloid/Lymphoid Neoplasms with Eosinophilia, Fox Chase Cancer Center Myeloproliferative Neoplasms, Neoplasms Emily Armgardt, PharmD, BCOP Robert
https://www.nccn.org/compendia-templates/nccn-templates-main/nccn-chemotherapy-order-reviewer-engagementAdvocacy and Support Groups
Myeloproliferative Neoplasms Neuroendocrine Tumors Ovarian Cancer Pancreatic Cancer Prostate Cancer, Association is a global nonprofit organization supporting people impacted by all histiocytic, awareness for all histiocytic disorders, and funding research that will lead us to cures, including histiocytic sarcoma, and diabetes inspidus (known as Arginine Vasopressin Deficiency or AVP
https://www.nccn.org/patientresources/patient-resources/resources-for-patients-caregivers/advocacy-and-support-groupsSubmission Request History
for Uterine Neoplasms Submitted by Bristol-Myers Squibb Company on 12/04/2019 Pembrolizumab for Uterine Neoplasms Submitted by Merck & Co., Inc. on 03/19/2020 Pembrolizumab Submitted, Pembrolizumab dosing for Uterine Neoplasms Submitted by Merck & Co., Inc. on 04/29/2020 Systemic Therapy Table Headings for Uterine Neoplasms Submitted by GlaxoSmithKline on 05/15/2020, for Uterine Neoplasms Submitted by Merck & Co., Inc. on 06/17/2020 Pembrolizumab for Vulvar
https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-historyAnnual Report 2023
neoplasms. These clinical resources were also translated into Chinese by leading experts in the region
https://www.nccn.org/docs/default-source/about/annual-report-2023.pdf?sfvrsn=8411082_31